INTERNATIONAL PATENT: EISBACH BIO GMBH, DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS, UNIVERSITAT DUISBURG-ESSEN KORPERSCHAFT DES OFFENTLICHEN RECHTS FILES APPLICATION FOR "ALC1 INHIBITORS ALC1I-1 AND ALC1I-2 FOR USE IN TREATING PANCREATIC CANCER BY POTENTIATING THE EFFECT OF IRINOTECAN"

GENEVA, May 12 -- EISBACH BIO GMBH (Am Klopferspitz 1982152 Martinsried), DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS (Im Neuenheimer Feld 28069120 Heidelberg), UNIVERSITAT DUISBURG-ESSEN KORPERSCHAFT DES OFFENTLICHEN RECHTS (Universitatsstrasse 245141 Essen) filed a patent application (PCT/EP2024/080878) for "ALC1 INHIBITORS ALC1I-1 AND ALC1I-2 FOR USE IN TREATING PANCREATIC CANCER BY POTENTIATING THE EFFECT OF IRINOTECAN" on Oct 31, 2024. With publication no. WO/2025/093706, the details related to the patent application was published on May 08, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organizati...